GlassScriptPhysician profile
Steven D Maness
NPI 1700872785
$5,345.47
in general payments reported to CMS, 2019-2025
37 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $412 · 2021: $944 · 2022: $686 · 2023: $1,184 · 2024: $836 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317 · Education: $92.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.70 |
| Education | $92.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $781.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $735.03 | 2019-2024 | Eliquis, Camzyos |
| Amgen INC. | $726.23 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $443.99 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $278.48 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $251.29 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.27 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $201.90 | 2019-2021 | |
| Boston Scientific Corporation | $198.79 | 2019-2021 | |
| Abbvie INC. | $187.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.68 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $147.07 | 2019-2022 | |
| Novo Nordisk INC | $142.61 | 2019-2025 | Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $128.37 | 2024-2025 | Voquezna |
| Hologic Sales and Service, LLC | $115.59 | 2023 | Thinprep 2000 Processor, Aptima |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.83 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $71.49 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $58.75 | 2019-2025 | Austedo Xr |
| Exact Sciences Corporation | $43.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $36.48 | 2020 | |
| Organon LLC | $30.23 | 2023 | Nexplanon |
| Abbott Laboratories | $24.20 | 2025 | Proclaim |
| Alfasigma USA, INC. | $23.13 | 2022 | |
| Daiichi Sankyo INC. | $22.91 | 2021 | |
| Edwards Lifesciences Corporation | $21.00 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Averitas Pharma INC. | $19.19 | 2024 | Qutenza |
| Si-Bone, INC. | $18.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.35 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.43 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.62 | 2024 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $14.01 | 2022 | |
| Lilly USA, LLC | $13.86 | 2020 | |
| Lundbeck LLC | $13.63 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $13.46 | 2021 | |
| Coala Life INC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Maness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.